Media Articles Related to Azilect (Rasagiline)
After substantia nigra injury in Parkinson's disease, iron accumulation suppressed by baicalin
Source: Neurology / Neuroscience News From Medical News Today [2014.08.29]
A growing number of studies have shown that excessive iron is closely associated with the pathogenesis of Parkinson's disease.
Patients with Parkinson's Disease often suffer from undiagnosed depression
Source: Depression News From Medical News Today [2014.08.19]
Depression is known to be a common symptom of Parkinson's disease, but remains untreated for many patients, according to a new study by Northwestern Medicine investigators in collaboration with the...
Source: MedicineNet amantadine Specialty [2013.12.04]
Title: Parkinson's Disease
Category: Diseases and Conditions
Created: 12/31/1997 12:00:00 AM
Last Editorial Review: 12/4/2013 12:00:00 AM
Parkinson's Disease Quiz: Test Your Medical IQ
Source: MedicineNet levodopa-carbidopa Specialty [2011.08.31]
Title: Parkinson's Disease Quiz: Test Your Medical IQ
Category: MedicineNet Quiz
Created: 8/23/2011 12:53:00 PM
Last Editorial Review: 8/31/2011 2:27:29 PM
Unprecedented detail of intact neuronal receptor should serve as template and guide for the design of therapeutic compounds
Source: Depression News From Medical News Today [2014.08.29]
Scientists succeeded in obtaining an unprecedented view of a type of brain-cell receptor that is implicated in a range of neurological illnesses, including Alzheimer's disease, Parkinson's disease...
Published Studies Related to Azilect (Rasagiline)
A double-blind, delayed-start trial of rasagiline in Parkinson's disease (the ADAGIO study): prespecified and post-hoc analyses of the need for additional therapies, changes in UPDRS scores, and non-motor outcomes. [2011.05]
BACKGROUND: The ADAGIO study investigated whether rasagiline has disease-modifying effects in Parkinson's disease. Rasagiline 1 mg per day, but not 2 mg per day, was shown to be efficacious in the primary analysis. Here, we report additional secondary and post-hoc analyses of the ADAGIO study... INTERPRETATION: These findings show that rasagiline delayed the need for symptomatic antiparkinsonian drugs and emphasise the contribution of the UPDRS ADL in the response of the rasagiline 1 mg per day early-start versus delayed-start group. The rate of UPDRS deterioration was less than was anticipated from previous studies and correlated with baseline severity. Understanding of the pattern of UPDRS deterioration is essential to assess disease modification. FUNDING: Teva Pharmaceutical Industries and H Lundbeck A/S. Copyright (c) 2011 Elsevier Ltd. All rights reserved.
Clinical pharmacology tyramine challenge study to determine the selectivity of the monoamine oxidase type B (MAO-B) inhibitor rasagiline. [2010.12]
Rasagiline is a selective, monoamine oxidase (MAO)-B inhibitor indicated for treatment of Parkinson's disease. This double-blind, placebo-controlled study determined the tyramine sensitivity factor (TSF) and degree of MAO-A inhibition (ie, reduction in plasma dihydroxyphenylglycol) in healthy volunteers who received phenelzine (15 mg, 3 times daily; positive control), selegiline (5 mg, twice daily), or rasagiline (1-6 mg, once daily) for 14 days or rasagiline 2 mg/d for 30 days...
Long-term efficacy of rasagiline in early Parkinson's disease. [2010.06]
This study was designed to follow the long-term efficacy, safety, and tolerability of rasagiline for Parkinson's disease (PD) with data collected from all patients who had ever taken rasagiline during the 12-month TEMPO monotherapy trial (N = 398) and subsequent open-label extension... Rasagiline therapy for PD was effective, well tolerated, and safe in this long-term trial.
The role of rasagiline in the treatment of Parkinson's disease. [2010.05.25]
Parkinson's disease (PD) is the second most common neurodegenerative disorder, affecting 1% to 2% of people older than 60 years. Treatment of PD consists of symptomatic therapies while neuroprotective strategies have remained elusive.The recently completed delayed-start ADAGIO (Attenuation of Disease Progression with Azilect Given Once-daily) trial suggests a potential disease-modifying effect for rasagiline 1 mg/day, though the clinical import of this finding has yet to be established.
Clinical pharmacology tyramine challenge study to determine the selectivity of
the monoamine oxidase type B (MAO-B) inhibitor rasagiline. 
Rasagiline is a selective, monoamine oxidase (MAO)-B inhibitor indicated for
treatment of Parkinson's disease. This double-blind, placebo-controlled study
determined the tyramine sensitivity factor (TSF) and degree of MAO-A inhibition
(ie, reduction in plasma dihydroxyphenylglycol) in healthy volunteers who
received phenelzine (15 mg, 3 times daily; positive control), selegiline (5 mg,
twice daily), or rasagiline (1-6 mg, once daily) for 14 days or rasagiline 2 mg/d
for 30 days...
Clinical Trials Related to Azilect (Rasagiline)
A Non-Blinded Study Demonstrating the Effectiveness and Safety of Azilect Alone or in Combination Therapy in Parkinson's Disease [Completed]
Patients with Parkinson's Disease (PD) will be divided into 2 groups at each study center at
their first visit based on the drugs they are taking for their PD:
- Group 1 Patients using Azilect and no other therapy.
- Group 2 Azilect in combination with other medications like Levodopa, Mirapex, or
Study to Evaluate the Effects of Azilect® on Sleep Disturbances in Parkinson's Disease [Recruiting]
Study of Rasagiline in Levodopa-treated PD Patients With Motor Fluctuations [Recruiting]
To evaluate the efficacy of a fixed dose of rasagiline (1 mg/day) vs placebo as assessed by
the change from baseline in mean total daily OFF time during 18 weeks of treatment in
levodopa-treated Parkinson's Disease (PD) patients with motor fluctuations.
Rasagiline in Cognitive-impairment Related Depression: AzileCt in COgnitive-impairment Related DepressiOn [Recruiting]
The primary endpoint for this study is the clinical response after 12 weeks of treatment,
defined as a change in total score from baseline depressive symptoms as measured by the Beck
Depression Inventory-Amended (BDI-IA) total score.
A Study Assessing Change in Sense of Smell After Rasagiline Use in Parkinson's Patients [Recruiting]
A decrease or loss of the sense of smell is very common in patients with Parkinson's Disease
even in the earliest stages of the disease. There have been no treatments that have been
proven to improve sense of smell in patients with Parkinson's Disease.
Rasagiline (brand name: Azilect) was approved by the U. S. Food and Drug Administration (FDA)
on May 16th 2006 to be used by Parkinson's patients to treat the motor symptoms associated
with the disease. The purpose of this study is to see if there is change in sense of smell
after starting Rasagiline.
Reports of Suspected Azilect (Rasagiline) Side Effects
Drug Interaction (14),
Confusional State (8), more >>